{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27.0","upperLimit":"59.1","value":"42.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants with BOR as CR or PR based on the RECIST v1.1 as per investigator's assesment. CR was defined as disappearance of all target and nontarget lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \\< 10 mm from baseline measurement. PR was defined as at least a 30% decrease in the sum of diameters (longest for nonnodal lesions, short axis for nodal lesions) of target lesions taking as reference to the baseline sum of diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 1.25 mg/kg of body weight enfortumab vedotin by IV infusion over approximately 30 minutes on days 1, 8 and 15 of every 28-day cycle. Participants received study treatment until radiological disease progression as determined per investigator assessment or other discontinuation criteria were met or upon study termination, or study completion, whichever occurred first.","id":"OG000","title":"Enfortumab Vedotin 1.25 mg/kg"}],"paramType":"NUMBER","populationDescription":"FAS population","reportingStatus":"POSTED","timeFrame":"From first dose up to progressive disease or death (maximum duration: 9.33 months)","title":"Objective Response Rate (ORR) as Per Investigator Assessment","type":"SECONDARY","unitOfMeasure":"percentage of participants"}